BioServe has acquired Genomics Collaborative
BioServe announced that it has acquired genomics Collaborative from SeraCare Life Sciences, Inc. According to BioServe, Genomics Collaborative is a leader in facilitating biomarker discovery and validation through its Global Repository®, a comprehensive library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients collected on four continents.
Through this acquisition BioServe expands its pre-clinical product and service capabilities to provide organizations engaged in drug discovery and diagnostic development with a comprehensive "biomaterial to validated data" services platform. This service platform extends from molecular research products and services such as DNA and RNA purification reagents, DNA sequencing, oligonucleotide synthesis and genotyping to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and cancers including breast, prostate, lung and colorectal.
"The acquisition of Genomics Collaborative firmly positions BioServe as a preferred partner for pre-clinical discovery and validation studies. Working with BioServe, drug discovery researchers have the flexibility to tap the Bio Repository to augment their in house sample sets, design entire genomic studies around our sample library, and further benefit from BioServe's proven ability to process and analyze vast quantities of genomic content," said Rama Modali, President, BioServe. "BioServe's complete biomaterial to validated data approach will help researchers identify the genetics markers, biochemical pathways and drug targets that cause disease to accelerate the development of new and safer drugs."
Genomics Collaborative will operate as a fully integrated division of BioServe, offering its DNA, tissue and serum Global Repository® samples to BioServe's customers worldwide. The Genomics Collaborative clinical team, led by Vice President of Medical Affairs, George Taylor MD, has joined BioServe and will further add to the company's expertise in genomics, epidemiology, biostatistics and molecular biology.
Other news from the department business & finance
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Most read news
More news from our other portals
Last viewed contents
International_Medical_Informatics_Association
Merck Expands Production Know-how to Deliver Full End-To-End Solution for Biopharma Industry - Flexible factory concept allows accelerated drug development and delivery to market
Archibald_Hill
Haplogroup_R2_(Y-DNA)
How an Emerging Drug Class Dampens Harmful Immune Reactions - It wasn't until 2021 that a new therapy came on the market, in the form of a class of drugs called compstatins, to inhibit harmful immune responses of the complement system
Haplogroup_O2a_(Y-DNA)
